金石亚药(300434) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥362,785,115.79, a decrease of 13.58% compared to ¥419,787,729.70 in the same period last year[4] - Net profit attributable to shareholders was ¥89,816,224.68, down 37.39% from ¥143,460,482.45 year-on-year[4] - Basic and diluted earnings per share decreased by 37.38% to ¥0.2236 from ¥0.3571 in the same quarter last year[4] - The net profit for Q1 2024 was CNY 89,543,650.31, a decrease of 37.1% compared to CNY 142,497,992.18 in Q1 2023[15] - Operating profit for Q1 2024 was CNY 115,048,924.11, down from CNY 184,249,348.46 in the same period last year, reflecting a decline of 37.6%[15] - Total revenue from sales in Q1 2024 was CNY 221,959,957.20, compared to CNY 350,792,078.64 in Q1 2023, indicating a decrease of 36.6%[17] - The total comprehensive income for Q1 2024 was CNY 89,543,650.31, compared to CNY 142,497,992.18 in Q1 2023, reflecting a decrease of 37.1%[16] Cash Flow and Assets - The net cash flow from operating activities was -¥90,480,979.33, representing a decline of 56.84% compared to -¥57,691,400.00 in the previous year[4] - Cash and cash equivalents decreased to CNY 444,143,577.19 from CNY 545,898,926.96, reflecting a decline of 18.5%[11] - The cash flow from operating activities for Q1 2024 was negative CNY 90,480,979.33, worsening from negative CNY 57,691,400.00 in Q1 2023[19] - The total current assets decreased to CNY 1,344,736,190.86 from CNY 1,371,587,670.56, a decline of 2.0%[12] - Total non-current assets increased to CNY 1,760,658,774.68 from CNY 1,729,850,994.45, an increase of 1.8%[12] Equity and Liabilities - Total assets at the end of the reporting period were ¥3,105,394,965.54, a slight increase of 0.13% from ¥3,101,438,665.01 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 3.74% to ¥2,490,245,750.15 from ¥2,400,429,525.47[4] - Total liabilities decreased to CNY 591,785,286.41 from CNY 677,372,636.19, a reduction of 12.6%[13] - The total equity attributable to shareholders increased to CNY 2,490,245,750.15 from CNY 2,400,429,525.47, an increase of 3.7%[13] Operating Costs and Expenses - The total operating costs for the current period amount to CNY 247,274,368.45, an increase of 4.4% from CNY 236,336,112.04 in the previous period[14] - Research and development expenses decreased to CNY 8,503,028.08 in Q1 2024 from CNY 17,587,226.51 in Q1 2023, a reduction of 51.6%[15] - The company incurred financial expenses of CNY -1,432,158.76 in Q1 2024, compared to CNY -627,377.47 in Q1 2023, indicating an increase in financial costs[15] Market and Operational Insights - The overall market demand for cold medicine products stabilized in Q1 2024, contributing to the decline in revenue and profit[7] - The company experienced a decrease in sales prepayments, impacting the net cash flow from operating activities[7] - The company reported non-recurring gains of ¥2,172,349.82 during the quarter, including government subsidies and other income[5] - The company reported a significant reduction in employee compensation payable, decreasing to CNY 33,896,086.08 from CNY 75,786,697.07, a decline of 55.3%[13] - Inventory decreased to CNY 225,394,191.50 from CNY 238,164,264.61, a decrease of 5.2%[12] - Accounts receivable increased to CNY 100,957,025.89 from CNY 79,477,350.02, representing a growth of 27.1%[11]